Characterization of the DD23 tumor-associated antigen for bladder cancer detection and recurrence monitoring

Cancer Epidemiology Biomarkers and Prevention

Volumn 5, Issue 12, 1996, Pages 971-978

  Bonner, Rebecca B ^a   Liebert, Monica ^c   Hurst, Robert E ^a,b   Grossman, H Barton ^c   Bane, Barbara L ^a   Hemstrcet III, George P ^a,b  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY DD23; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADULT; ANTIGEN DETECTION; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; ARTICLE; BLADDER CANCER; CANCER RECURRENCE; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; HIGH RISK PATIENT; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; BLOTTING, WESTERN; CARCINOMA; FEMALE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; MALE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; PRECIPITIN TESTS; SENSITIVITY AND SPECIFICITY; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 0029845101     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Wingo, P. A., Tong, T., and Bolden, S. Cancer statistics, 1995. CA Cancer J. Clin., 45: 8-30, 1995.
2. Whelan, S. L., and Ferlay, J. Cancer Incidence in Five Continents: Age-specific and Standardized Incidence Rates, pp. 178-861. IARC Scientific Publ. No. 120. Lyon, France: IARC, 1992.
3. Cartwright, R. A. Screening workers exposed to suspect bladder carcinogens. J. Occup. Med., 28: 1017-1019, 1986.
4. Heney, N. M., Ahmed, S., Flanagan, M. J., Frable, W., Corder, M. P., Hafermann, M. D., and Hawkins, I. R. Superficial bladder cancer: progression and recurrence. J. Urol., 130: 1083-1086, 1983.
5. Koss, L. G. Tumors of the urinary tract and prostate. In: L. G. Koss (ed.), Diagnostic Cytology and Its Histologic Basis, pp. 749-811, Philadelphia: J. B. Lippincott Co., 1979.
6. Rao, J. Y., Hemstreet, G. P., Hurst, R. E., Bonner, R. B., Jones, P. L., Min, K. W., and Fradet, Y. Alterations in phenotypic biochemical markers in bladder epithelium during tumorigenesis. Proc. Natl. Acad. Sci. USA, 90: 8287-8291, 1993.
7. Vicente-Rodriguez, J., Chechile, G., Algaba, F., and Amaral, J. Value of random endoscopic biopsy in the diagnosis of bladder carcinoma in situ. Eur. Urol., 13: 150-152, 1987.
8. Ruder, A., Fine, L., and Sundin, D. National estimates of occupational exposure to animal bladder tumorigens. J. Occup. Med., 32: 797-805, 1990.
9. Bi, W. F., Hayes, R., Feng, P., Qi, Y., You, X., Zhen, J., Zhang, M., Qu, B., Fu, Z., Chen, M., Chien, H. T., and Blot, W. J. Mortality and incidence of bladder cancer in benzidine-exposed workers in China. Am. J. Ind. Med., 21: 481-489, 1992.
10. Lieben, M., Wedemeyer, G. A., Stein, J. A., Washington, R. W., Jr., Flint, A., Ren, L. Q., and Grossman, H. B. Identification by monoclonal antibodies of an antigen shed by human bladder cancer cell. Cancer Res., 49: 6720-6726, 1989.
11. Bonner, R. B., Hemstreet, G. P., Fradet, Y., Rao, J. Y., Min, K. W., and Hurst, R. E. Bladder cancer risk assessment with quantitative fluorescence image analysis of tumor markers in exfoliated bladder cells. Cancer (Phila.), 72: 2461-2469, 1993.
12. Hemstreet, G. P., Hurst, R. E., and Asal, N. R. Biologic markers in the genitourinary system. In: P. A. Schulte and F. P. Perera (eds.), Molecular Epidemiology: Principles and Practices, pp. 469-495. San Diego, CA: Academic Press, Inc., 1993.
13. Barry, J. M., Fowler, F. J., O'Leary, M. P., Bruskewitz, R. C., Holtgrewe, H. L, Mebust, W. K., Cockett, A. T. K., and The Measurement Committee of the American Urological Association. The American Urological Association symptom index for benign prostatic hyperplasia. J. Urol., 148: 1549-1557, 1992.
14. Jones, P. L., O'Hare, C., Bass, R. A., Rao, J. Y., Hemstreet, G. P., and Hurst, R. E. Quantitative immunofluorescence, anti-ras p21 antibody specificity and cellular oncoprotein levels. Biochem. Biophys. Res. Commun., 167: 464-470, 1990.
15. Rao, J. Y., Hurst, R. E., Bales, W. D., Jones, P. L., Bass, R. A., Archer, L. T., and Hemstreet, G. P. Cellular f-actin levels as a marker for cellular transformation: relationship to cell division and differentiation. Cancer Res., 50: 2215-2220, 1990.
16. Hanley, J. A. Receiver operating characteristic (ROC) methodology: the state of the art. Crit. Rev. Diagn. Imaging, 29: 307-335, 1989.
17. Grossman, H. B., Wedemeyer, G., Ren, L., Wilson, G. N., and Cox, G. Improved growth of human urothelial carcinoma cell cultures. J. Urol., 16: 953-959, 1986.
18. Towbin, H., Staehlin, T., and Gordon, J. Electrophoretic transfer of proteins from polyacrylamide gels into nitrocellulose sheets: procedure and some applications. Proc. Natl. Acad. Sci. USA, 76: 4350-4354, 1979.
19. Liebert, M., Wedemeyer, G., Stein, J. A., Washington, R. W., Jr., Van Waes, C., Carey, T. E., and Grossman, H. B. The monoclonal antibody BQ16 identifies the α6 β4 integrin on bladder cancer. Hybridoma, 12: 67-80, 1993.
20. Laemmli, U. K. Cleavage of structured protein during the assembly of the head of bacteriophage T4. Nature (Lond.), 227: 680-685, 1970.
21. Kappler, J. W., Roehm, N., and Marrack, P. T-cell tolerance by clonal elimination in the thymus. Cell, 49: 273-280, 1987.
22. Grossman, H. B., Washington, R. W., Jr., Carey, T. E., and Liebert, M. Alterations in antigen expression in superficial bladder cancer (Review). J. Cell. Biochem., 16: 63-68, 1992.
23. Sidransky, D., Frost, P., von Eischenbach, A. C., Dyasu, R., Preisinger, A. C., and Vogelstein, B. Clonal origin bladder cancer. N. Engl. J. Med., 326: 759-761, 1992.
24. Fradet, Y., Tardif, M., Beuget, L., and Robert, J. Clinical cancer progression in urinary bladder tumors evaluated by multiparameter flow cytometry with monoclonal antibodies. Cancer Res., 50: 432-437, 1990.
25. Fradet, Y. Molecular and immunologic approaches in the management of bladder cancer. Urol. Clin. North Am., 18: 515-524, 1991.
26. Fradet, Y., LaRue, H., Parent-Vaugeois, C., Bergeron, A., Dufour, C., Boucher, L., and Bernier, L. Monoclonal antibody against a tumor-associated sialoglycoprotein of superficial papillary bladder tumors and cervical condylomas. Int. J. Cancer, 46: 990-997, 1990.
27. Huland, E., Huland, H., Meier, T., Baricordi, O. R., Fradet, Y., Grossman, H. B., Hodges, G. M., Messing, E. M., and Schmitz-Draeger, B. J. Comparison of 15 monoclonal antibodies against tumor-associated antigens of transitional cell carcinoma of the human bladder. J. Urol., 146: 1631-1636, 1991.
28. Cordon-Cardo, C., Wartinger, D. D., Melamed, M. R., Fair, W., and Fradet, Y. Immunopathologic analysis of human urinary bladder cancer. Characterization of two new antigens associated with low-grade superficial bladder tumors. Am. J. Pathol., 140: 375-385, 1992.
29. Nathan, C., and Sporn, M. Cytokines in context. J. Cell Biol., 113: 981-986, 1991.
30. Presti, J. C., Jr., Reuter, V. E., Galan, T., Fair, W. R., and Cordon-Cardo, C. Molecular genetic alterations in superficial and locally advanced human bladder cancer. Cancer Res., 51: 5405-5409, 1991.
31. Spruck, C. H., III, Ohneseit, P. F., Gonzalez-Zulueta, M., Esrig, D., Miyao, N., Tsai, Y. C., Lerner, S. P., Schmütte, C., Yang, A. S., Cote, R., Dubeau, L., Nichols, P. W., Hermann, G. G., Steven, K., Horn, T., Skinner, D. G., and Jones, P. A. Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res., 54: 784-788, 1994.
32. Clark, E. A., and Brugge, J. S. Integrins and signal transduction pathways: the road taken. Science (Washington DC), 268: 233-239, 1995.
33. Artavanis-Tsakonas, S., Matsuno, K., and Fortini, M. E. Notch signaling. Science (Washington DC), 268: 225-232, 1995.
34. Ghosh, A., and Greenberg, M. E. Calcium signaling in neurons: molecular mechanisms and cellular consequences. Science (Washington DC), 268: 239-247, 1995.
35. Mochly-Rosen, D. Localization of protein kinases by anchoring proteins: a theme in signal transduction. Science (Washington DC), 268: 247-251, 1995.
36. Taniguchi, T. Cytokine signaling through nonreceptor protein tyrosine kinases. Science (Washington DC), 268: 251-255, 1995.
37. Casey, P. J. Protein lipidation in cell signaling. Science (Washington DC), 268: 221-225, 1995.
38. SEER Cancer Statistics Review, 1973-1991, p. 422. NIH Publ. No. 94-2789. Bethesda, MD: National Cancer Institute, 1994.
39. Messing, E. M., and Vaillancourt, A. Hematuria screening for bladder cancer. J. Occup. Med., 32: 838-845, 1990.
40. Britton, J., Dowell, A., and Whelan, P. Dipstick haematuria and bladder cancer in men over 60: results of a community study. Br. Med. J., 299: 1010-1012, 1989.
41. Hemstreet, G. P., Bonner, R. B., Hurst, R. E., and O'Dowd, G. A. Cytology of bladder cancer. In: N. J. Vogelzang, P. T. Scardino, W. U. Shipley, and D. S. Coffey (eds.), Comprehensive Textbook of Genitourinary Oncology, pp. 338-350. Baltimore, MD: Williams & Wilkins, 1996.